Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture ...